Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 5,498 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo once daily Clear all
Recruiting Phase 4 Interventional

Vitamin D Homeostasis in Sarcoidosis

NCT03621553
View directory record Official record
Conditions
Sarcoidosis, Vitamin D Insufficiency
Interventions
Ergocalciferol, Placebo, Calcium Citrate with Vitamin D2
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 17, 2026, 9:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of a Dietary Supplement on Parameters of Skin Aging in Men and Women

NCT06083402
View directory record Official record
Conditions
Skin Aging
Interventions
HyaCera™, Placebo
Dietary Supplement
Lead sponsor
Natals, Inc. dba Ritual
Industry
Eligibility
25 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 17, 2026, 9:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2216684 in Healthy Females

NCT01373931
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
LY2216684, Ortho Cyclen, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 17, 2026, 9:37 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

NCT01469377
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Cariprazine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
819 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
39
States / cities
Garden Grove, California • National City, California • Oceanside, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 17, 2026, 9:37 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

NCT01200394
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
PF-00489791, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
63
States / cities
Huntsville, Alabama • Glendale, Arizona • Tempe, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 17, 2026, 9:37 AM EDT
Completed Phase 2 Interventional

Dose Range Finding Study of Fedovapagon in Men With Nocturia

NCT01656239
View directory record Official record
Conditions
Nocturia
Interventions
fedovapagon 1 mg, fedovapagon 2 mg, fedovapagon 4 mg, Placebo ( sugar pill)
Drug
Lead sponsor
Vantia Ltd
Industry
Eligibility
55 Years and older · Male only
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
56
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Oct 17, 2026, 9:37 AM EDT
Completed Phase 1 Interventional

Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test

NCT03004339
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
SOR007 Ointment 2.0%, SOR007 Ointment 1.0%, SOR007 Ointment 0.3%, SOR007 Ointment 0.15%, SOR007 Ointment Placebo, Taclonex® Ointment
Drug
Lead sponsor
DFB Soria, LLC
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 17, 2026, 9:37 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp

NCT03285477
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Placebo, KX2-391 Ointment 1%
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Mobile, Alabama • Glendale, Arizona • Fremont, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 17, 2026, 9:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease

NCT04031729
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Interventions
Aspirin 81 mg, Placebo oral tablet
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 17, 2026, 9:37 AM EDT
Completed Phase 3 Interventional Results available

Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

NCT00121641
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Saxagliptin, Placebo matching Saxagliptin, Metformin, Placebo matching Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
83
States / cities
Anniston, Alabama • Birmingham, Alabama • Calera, Alabama + 80 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 17, 2026, 9:37 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)

NCT03268941
View directory record Official record
Conditions
Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis
Interventions
TAK-906 Maleate, Metaclopramide, TAK-906 Maleate Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Peoria, Arizona • Tucson, Arizona • Little Rock, Arkansas + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 17, 2026, 9:37 AM EDT
Completed Phase 3 Interventional Results available

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

NCT03057951
View directory record Official record
Conditions
Heart Failure
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
5,988 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
135
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 17, 2026, 9:37 AM EDT
Completed Phase 4 Interventional Results available

Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder

NCT00429273
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Guanfacine, Methylphenidate (MPH)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
7 Years to 14 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 17, 2026, 9:37 AM EDT
Recruiting Early Phase 1 Interventional

Efficacy of a Topical Palmitated Formulation of Capsaicin (Capsadyn®) In the Treatment of Diabetic Neuropathic Foot Pain

NCT07260656
View directory record Official record
Conditions
Diabetic Neuropathies, Painful, Diabetic Foot, Diabetic Peripheral Neuropathy
Interventions
Capsaicin Palmitate, Placebo
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
25 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 17, 2026, 9:37 AM EDT
Terminated Phase 2 Interventional

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

NCT01679951
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, JNJ-38518168 (3 mg), JNJ-38518168 (10 mg), JNJ-38518168 (30 mg), Methotrexate
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 17, 2026, 9:37 AM EDT
Completed Phase 2 Interventional Results available

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

NCT04129931
View directory record Official record
Conditions
Asthma
Interventions
MCT, Clazakizumab, Broncho-Vaxom, Imatinib Mesylate, Cavosonstat, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
29
States / cities
Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 17, 2026, 9:37 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Depression-Diabetes Mechanisms: Urban African Americans

NCT00209170
View directory record Official record
Conditions
Diabetes, Depression
Interventions
Beating the Blues, Escitalopram, Placebo
Behavioral · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 81 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Oct 17, 2026, 9:37 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use

NCT00535769
View directory record Official record
Conditions
Skin Cancer
Interventions
Electronic + no text message, Electronic monitor + text messages
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 17, 2026, 9:37 AM EDT
Terminated Phase 4 Interventional Results available

Naltrexone/Bupropion Cardiovascular Outcomes Study

NCT02638129
View directory record Official record
Conditions
Obesity, Cardiovascular Diseases
Interventions
Naltrexone HCl/Bupropion HCl ER, Placebo
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
139
States / cities
Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 17, 2026, 9:37 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)

NCT01587144
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Lucanthone, Temozolomide (TMZ), Radiation, Placebo
Drug · Radiation
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
La Jolla, California • Orange, California • Amherst, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 17, 2026, 9:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Varenicline and Nicotine Interactions in Humans (VA)

NCT00606892
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline, Placebo, IV Nic
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 17, 2026, 9:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Smoking Environments on Craving and Smoking (CameraCue2.0)

NCT02551692
View directory record Official record
Conditions
Cigarette Smoking
Interventions
Nicotine Patch, Varenicline, Placebo Nicotine Patch, Placebo Capsule
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 17, 2026, 9:37 AM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD

NCT00749411
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo, GSK233705/GW642444
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Mobile, Alabama • Wheat Ridge, Colorado • Biddeford, Maine + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 17, 2026, 9:37 AM EDT
Recruiting Phase 3 Interventional

A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

NCT07673887
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
ASP2138, Pembrolizumab, Oxaliplatin, Capecitabine, Folinic acid, 5-FU, Placebo for ASP2138, Placebo for Pembrolizumab
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 17, 2026, 9:37 AM EDT